Johnson & Johnson (JNJ) Stake Decreased by Financial Advisory Group
Financial Advisory Group lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,967 shares of the company’s stock after selling 14 shares during the quarter. Financial Advisory Group’s holdings in Johnson & Johnson were worth $789,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently bought and sold shares of JNJ. Lenox Wealth Advisors Inc. grew its position in Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after buying an additional 5 shares during the last quarter. Premier Asset Management LLC grew its position in Johnson & Johnson by 0.4% in the second quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock worth $363,000 after buying an additional 12 shares during the last quarter. Halbert Hargrove Russell LLC grew its position in Johnson & Johnson by 0.4% in the second quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock worth $466,000 after buying an additional 15 shares during the last quarter. Stratford Consulting LLC grew its position in Johnson & Johnson by 0.6% in the second quarter. Stratford Consulting LLC now owns 2,728 shares of the company’s stock worth $361,000 after buying an additional 16 shares during the last quarter. Finally, Iron Financial LLC grew its position in Johnson & Johnson by 0.5% in the second quarter. Iron Financial LLC now owns 3,782 shares of the company’s stock worth $500,000 after buying an additional 19 shares during the last quarter. Institutional investors and hedge funds own 65.90% of the company’s stock.
JNJ has been the topic of several recent research reports. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Royal Bank Of Canada lifted their price target on shares of Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 18th. Citigroup initiated coverage on shares of Johnson & Johnson in a research report on Monday, September 25th. They issued a “neutral” rating and a $140.00 price target on the stock. Goldman Sachs Group lowered shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and lifted their price target for the stock from $125.00 to $130.00 in a research report on Wednesday, September 20th. Finally, Jefferies Group raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price objective for the stock from $145.00 to $157.00 in a research note on Wednesday, October 11th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $144.59.
Shares of Johnson & Johnson (NYSE JNJ) traded down $0.97 during trading hours on Tuesday, hitting $139.01. 5,916,600 shares of the company’s stock were exchanged, compared to its average volume of 5,873,962. The firm has a market cap of $376,059.06, a price-to-earnings ratio of 19.60, a P/E/G ratio of 2.85 and a beta of 0.80. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $144.35. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. The company had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the business posted $1.68 EPS. sell-side analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.42%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 58.33%.
ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) Stake Decreased by Financial Advisory Group” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/johnson-johnson-jnj-stake-decreased-by-financial-advisory-group/1745258.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.